SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- Anadys
Pharmaceuticals, Inc. (Nasdaq: ANDS) is updating the date and time
of the Company's presentation at the Stifel Nicolaus Healthcare
Conference to Thursday, September 8,
2011 at 4:25 p.m. EDT
(1:25 p.m. PDT). The conference
is being held at the Four Seasons Hotel in Boston. Steve Worland, Ph.D., President
and Chief Executive Officer of Anadys, will provide an overview of
Anadys and its clinical development programs, setrobuvir and
ANA773.
The presentation will be webcast at the time of presentation and
can be accessed on the Investor Relations page of the Company's
website at www.anadyspharma.com. Listeners are encouraged to
visit the website approximately five minutes prior to the
presentation to download or install any necessary software. A
replay of the presentation will be available approximately one hour
after the live webcast concludes and will be available through
September 22, 2011.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to improving patient care by developing novel medicines
for the treatment of hepatitis C. The Company believes
hepatitis C represents a large unmet medical need in which
meaningful improvements in treatment outcomes may be attainable
with the introduction of new medicines. Anadys is conducting
a Phase IIb study of setrobuvir, the Company's DAA, added to
pegylated interferon and ribavirin for the treatment of hepatitis
C. The Company is also developing ANA773, the Company's
oral, small-molecule inducer of endogenous interferons that acts
via the Toll like receptor 7, or TLR7, pathway in hepatitis C and
plans to initiate a Phase IIa study shortly.
Safe Harbor Statement
Statements in this press release that are not strictly
historical in nature constitute "forward-looking statements."
Such forward-looking statements involve known and unknown
risks, uncertainties and other factors, which may cause Anadys'
actual results to be materially different from historical results
or from any results expressed or implied by such forward-looking
statements. For example, the results of preclinical and early
clinical studies may not be predictive of future results, and
Anadys cannot provide any assurances that setrobuvir (ANA598) or
ANA773 will not have unforeseen safety issues, will have favorable
results in ongoing or future clinical trials or will receive
regulatory approval. In addition, Anadys' results may be affected
by competition from other biotechnology and pharmaceutical
companies, its effectiveness at managing its financial resources,
its ability to enter into transactions around its product
candidates, its ability to successfully develop and market
products, difficulties or delays in its non-clinical studies or
clinical trials, difficulties or delays in manufacturing its
clinical trials materials, the scope and validity of patent
protection for its products, regulatory developments and its
ability to obtain additional funding to support its operations.
Risk factors that may cause actual results to differ are more
fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q
for the quarter ended June 30, 2011.
All forward-looking statements are qualified in their
entirety by this cautionary statement. Anadys is providing
this information as of this date and does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
SOURCE Anadys Pharmaceuticals, Inc.